Skip to Main Content
Capabilities / Psychedelics & Emerging Therapies

Psychedelics & Emerging Therapies

Deep and growing experience assisting clients with the complex legal and regulatory requirements of emerging therapies.

Husch Blackwell has a long track record in counseling those engaged in research and commercialization of novel—and controversial—therapies. We were one of the first large national law firms to establish a practice group devoted to cannabis, and as the utility and acceptance of psychedelic therapies have gained a foothold across the medical community, our firm is once again at the forefront in developing a multidisciplinary team to represent clients in this growing area of treatment.

Similar to the early days of the medical cannabis movement, psychedelic drugs such as MDMA, psilocybin, LSD, ketamine, and DMT are emerging in a complex and difficult legal and regulatory environment that can frustrate efforts to develop new therapies. Our team guides researchers, manufacturers, investors, clinicians, and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances, including the Controlled Substances Act (CSA), Money Laundering Control Act (MLCA), various criminal statutes that cover the sale and consumption of psychedelics, and various state legal and regulatory regimes.

Our team is multidisciplinary by nature and integrates subject-matter authorities who can drill down into relevant issues at every phase of research, development, commercialization, and medical practice. We assist entrepreneurs and investors in forming ventures and developing governance structures best suited for operation in the psychedelic industry. Once established, clients turn to our regulatory and finance lawyers to assist with operationalizing and funding the enterprise. Our clients benefit from our attorneys’ comprehensive experience in Food & Drug Administration (FDA) regulations and scientific expertise, handling matters involving development of premarket strategies for controlled substances, preparing and prosecuting investigational new drug (IND) exemptions and new drug applications (NDA), compliance with current good manufacturing practice (cGMP) requirements applicable to botanical drug substances and products, as well as enforcement matters for pharmaceuticals, digital technologies, and medical devices. Additionally, our team comprises lawyers from our nationally recognized healthcare industry group who have deep experience with clinical trial frameworks, including third-party contracts with contract research organizations (CROs), principal investigators (PIs), and contract manufacturers of investigational drug substances and products; informed consent; and interactions with institutional review boards (IRBs) concerning protocols and study monitoring. Further, we have assisted businesses in opening ketamine clinics, handling issues ranging from corporate formation to compliance with healthcare regulations in various states.   

Our team provides its psychedelic and emerging therapies clients with a full suite of legal services that bear upon the development of new products and therapies, including:

  • Corporate
  • Corporate & Medical Real Estate
  • Employee Benefits & Executive Compensation
  • FDA, DEA, and State Law Regulation and Compliance
  • Immigration
  • Intellectual Property
  • International Trade & Supply Chain
  • Labor & Employment
  • Litigation & Alternative Dispute Resolution
  • Products Liability
  • Securities & Corporate Governance
  • Tax
Blog | February 05, 2024
Advancing Military Mental Health
Podcast | September 12, 2023
Psytelligence Podcast
Articles | June 23, 2023
Beyond the Psychedelic Renaissance
Articles | June 23, 2023
Conducting Psychedelic Clinical Trials
Articles | September/October 2022: | Volume 39, Issue 5
GPSolo Magazine: Legal Developments in Psychedelic Therapeutics
Articles | June 2022 | Volume 34, Number 5
The Health Lawyer: Legal Developments in Psychedelic Therapeutics
Webinar | June 27, 2024
Emerging Trends in Clinical Trials
Webinar | July 25, 2023
Hot Topics in Psychedelic Law
News Releases | February 17, 2023
Husch Blackwell Authors Amicus Brief in Ninth Circuit's Psilocybin Rescheduling Dispute

Husch Blackwell prepared and filed an amicus curiae brief on behalf of nearly 30 end-of-life and palliative care clinicians, urging the U.S. Court of Appeals for the Ninth Circuit to compel the U.S. Drug Enforcement Agency to initiate proceedings that could lead to a rescheduling of psilocybin for use in the end-of-life clinical setting.

News Releases | March 15, 2022
Husch Blackwell Launches Psychedelics and Emerging Therapies Practice Group

Husch Blackwell is pleased to announce the formalization of its Psychedelics and Emerging Therapies practice group, making it the first Am Law 100 firm to establish such a practice.